Australia
· Delayed Price · Currency is AUD Radiopharm Theranostics Company Description
Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs.
It develops RAD 204, a programmed death-ligand 1 (PD-L1) for the treatment of non-small cell lung cancer (NSCLC); RAD 202, a human epidermal growth factor receptor 2 (HER2) to treat breast cancer and other solid tumors; and RAD 301, a diagnostic radiopharmaceutical targeting αvβ6 integrin in pancreatic ductal adenocarcinoma patients.
The company also develops RAD 302, an αvβ6-integrin targeting agent for the treatment of multiple cancer types; RAD 101 and RAD 102 for brain metastases; RAD 402 to treat advanced prostate cancer; and RV01 for multiple solid tumors.
It has strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals.
The company was incorporated in 2021 and is based in Carlton, Australia.
| Country | Australia |
| Founded | 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Riccardo Canevari |
Contact Details
Address: 62 Lygon Street Carlton, 3053 Australia | |
| Phone | 61 3 9824 5254 |
| Website | radiopharmtheranostics.com |
Stock Details
| Ticker Symbol | RAD |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU0000181851 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Riccardo Canevari | MD, Chief Executive Officer and Director |
| Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD | Founder and Executive Chairman |
| Phillip Hains | Chief Financial Officer, Joint Company Secretary and Director |
| Dr. Dimitris Voliotis M.D. | Chief Medical Officer |
| Hitesh Goel | Head of Project Management |
| Nathan Jong C.A. | Joint Company Secretary |